The Old Boys Club in New Zealand Listed Companies

by Chen Chen, David K. Ding, William R. Wilson
Published 2021-07-01

An Intratumor Pharmacokinetic/Pharmacodynamic Model for the Hypoxia-Activated Prodrug Evofosfamide (TH-302): Monotherapy Activity is Not Dependent on a Bystander Effect

by Cho Rong Hong, William R. Wilson, Kevin O. Hicks
Published 2019-02-01

Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell Cultures

by Cho R. Hong, Gib Bogle, Gib Bogle, Jingli Wang, Kashyap Patel, Frederik B. Pruijn, William R. Wilson, William R. Wilson, Kevin O. Hicks, Kevin O. Hicks
Published 2018-09-01

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors

by Benjamin D. Dickson, Way Wua Wong, William R. Wilson, Michael P. Hay
Published 2019-04-01

Design of optimized hypoxia-activated prodrugs using pharmacokinetic/pharmacodynamic modeling

by Annika Bettina Foehrenbacher, Timothy W. Secomb, William R. Wilson, Kevin O Hicks
Published 2013-12-01

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids.

by Xinjian Mao, Sarah McManaway, Jagdish K Jaiswal, Priyanka B Patel, William R Wilson, Kevin O Hicks, Gib Bogle
Published 2018-10-01

Zinc finger nuclease mediated knockout of ADP-dependent glucokinase in cancer cell lines: effects on cell survival and mitochondrial oxidative metabolism.

by Susan Richter, Shona Morrison, Tim Connor, Jiechuang Su, Cristin G Print, Ron S Ronimus, Sean L McGee, William R Wilson
Published 2013-01-01

The role of bystander effects in the antitumor activity of the hypoxia-activated prodrug PR-104

by Annika eFoehrenbacher, Kashyap ePatel, Maria eAbbattista, Chris P. Guise, Timothy W. Secomb, William R. Wilson, Kevin O. Hicks
Published 2013-10-01

Benzotriazine Di-Oxide Prodrugs for Exploiting Hypoxia and Low Extracellular pH in Tumors

by Michael P. Hay, Hong Nam Shin, Way Wua Wong, Wan Wan Sahimi, Aaron T.D. Vaz, Pooja Yadav, Robert F. Anderson, Kevin O. Hicks, William R. Wilson
Published 2019-07-01

Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models

by Julia K. Harms, Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, Francis W. Hunter, Andrew M. J. Macann, William R. Wilson, Stephen M.F. Jamieson
Published 2019-07-01

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity

by Chris P. Guise, Maria R. Abbattista, Robert F. Anderson, Dan Li, Rana Taghipouran, Angela Tsai, Su Jung Lee, Jeff B. Smaill, William A. Denny, Michael P. Hay, William R. Wilson, Kevin O. Hicks, Adam V. Patterson
Published 2020-10-01

Reductive Metabolism Influences the Toxicity and Pharmacokinetics of the Hypoxia-Targeted Benzotriazine Di-Oxide Anticancer Agent SN30000 in Mice

by Yongchuan Gu, Tony T.-A. Chang, Jingli Wang, Jagdish K. Jaiswal, David Edwards, Noel J. Downes, H. D. Sarath Liyanage, Courtney R. H. Lynch, Frederik B. Pruijn, Anthony J. R. Hickey, Michael P. Hay, William R. Wilson, Kevin O. Hicks
Published 2017-08-01

Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.

by Juliana Benito, Yuexi Shi, Barbara Szymanska, Hernan Carol, Ingrid Boehm, Hongbo Lu, Sergej Konoplev, Wendy Fang, Patrick A Zweidler-McKay, Dario Campana, Gautam Borthakur, Carlos Bueso-Ramos, Elizabeth Shpall, Deborah A Thomas, Craig T Jordan, Hagop Kantarjian, William R Wilson, Richard Lock, Michael Andreeff, Marina Konopleva
Published 2011-01-01